A Phase 2 interventional study of Pioglitazone + TKI in Chronic Myeloid Leukemia (CML), sponsored by Versailles Hospital. Recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Versailles Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France — 15 open to participants now, 24 under way, 4 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · France.
Among the 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France, this one is the 75th largest by planned enrollment of the 83 interventional ones that give a count, is one of 5 that started in 2016, is one of 33 in phase 2, reaches primary completion later than 11 of the 23 other live ones, and was the 67th registered.
895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →15 of the 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, United States, Australia and 14 more countries
Ages 1–18
Novartis Pharmaceuticals · Sites in France
Ages 18–99
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Sites in France, United States, Australia and 6 more countries
Ages 18+
Ascentage Pharma Group Inc. · Sites in France, United States, Australia and 13 more countries
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 42 · Phase 3 21 · Phase 4 5
First in 1999; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 26 is below the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 150 across the 83 interventional studies, 200 across the 19 observational. Of the 74 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 103 have an industry lead sponsor. The 10 most frequent:
Versailles Hospital is the lead sponsor of 74 studies on the registry; 16 are open to participants now.
Versailles Hospital has 3 studies filed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive — fewer than ten, so there is no comparison to draw.
3 of the studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06423911Phase 3Ascentage Pharma Group Inc.Study of Olverembatinib (HQP1351) in Patients With CML-CP | 2027-06-30 |
| NCT06092879Novartis PharmaceuticalsAsciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France | 2026-12-15 |
| NCT04925479Novartis PharmaceuticalsStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | 2027-09-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Single-center study, prospective, phase II trial.
The study objectives are :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pioglitazone + TKI
Drug page: PioglitazoneStudies of PioglitazonePioglitazone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: Up to 24 months after inclusion
Treatment free survival after pioglitazone and tyrosine kinase inhibitor discontinuation.
Time frame: Up to 24 months after inclusion
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Yes
No publications or documents are linked to this record.
Started Dec 2016 (actual). Primary completion is estimated for Dec 2027, 132 months after the start.
Of 99 non-industry phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 130. This study's planned 132 months is above that.
Counting every sponsor, half of 124 studies reached it within 73 months; a quarter within 42 and three quarters within 121.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pioglitazone
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →
Versailles Hospital